Crossmark

Monitoring of prostate-specific antigen in men with benign prostate enlargement receiving 5-alpha reductase inhibitors: a non-interventional, cross-sectional study of real-world practice of urologists in Spain and Brazil

Crossref DOI link: https://doi.org/10.1186/s12894-025-01701-1

Published Online: 2025-01-31

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Palacios, Juan Manuel

Kapse, Pratiksha

Cortes, Vanessa

Averbeck, Marcio Augusto

Alba, Alberto Budia

Somvanshi, Suryakant

da Costa Cruz, Danilo Souza Lima

Pereira, Fiona
License Information

Text and Data Mining valid from 2025-01-31

Version of Record valid from 2025-01-31
More Information

Article History

Received: 14 October 2024

Accepted: 23 January 2025

First Online: 31 January 2025

Declarations

:

: A central independent review board (Pearl Independent Institution Review Board) considered that the research had no risk or minimal risk to participants and was exempt from most of the requirements of the Federal Policy for the Protection of Human Subjects. Written informed consent was obtained from all participants. This study was conducted according to the ethical principles outlined in the Declaration of Helsinki.

: This study complied with all applicable laws in the relevant countries regarding participant privacy. Urologists completed consent forms before study participation. All patient data were de-identified so informed consent was not required.

: JMP, PK, VC and SS are employed by and hold financial equities in GSK. MAA, ABA, DSLdCC and FP declare that they have no competing interests.

Document is current

Any future updates will be listed below